Infigratinib in Recurrent High-Grade Glioma Patients
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- GBM
- Glioblastoma
- Glioma
- Type
- Interventional
- Phase
- Early Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04424966
- Collaborators
- Ivy Brain Tumor Center
- Barrow Neurological Institute
- QED Therapeutics
- Investigators
- Not Provided